North Carolina women may be interested in a study that shows genetic testing is more accurate than traditional tests when determining the risk of early-stage breast cancer spreading. The results were published in the New England Journal of Medicine on Aug. 24.
European researchers analyzed the medical outcomes of 6,693 breast cancer patients and found women who opted out of chemotherapy when a DNA test showed a low risk of the cancer spreading had five-year survivor rates similar to women who chose to undergo chemo. Agendia, the Amsterdam company that makes the genetic test, believes the study is groundbreaking and "could change clinical practice." It is estimated that around 35,000 U.S. women with early-stage breast cancer could avoid the ordeal of chemotherapy each year if the test was widely adopted.